Jeremy B. Hayden Sells 4,864 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,864 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.52, for a total value of $17,121.28. Following the completion of the sale, the insider now owns 153,823 shares of the company’s stock, valued at approximately $541,456.96. The trade was a 3.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sight Sciences Trading Down 2.6 %

Shares of Sight Sciences stock opened at $3.31 on Wednesday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The firm has a market cap of $168.00 million, a price-to-earnings ratio of -3.25 and a beta of 2.57. Sight Sciences, Inc. has a twelve month low of $3.29 and a twelve month high of $8.45. The business has a 50-day moving average price of $3.93 and a 200-day moving average price of $5.58.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. Equities research analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of Sight Sciences by 335.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company’s stock valued at $439,000 after acquiring an additional 53,658 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its position in Sight Sciences by 5.4% during the third quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after purchasing an additional 10,000 shares during the period. Barclays PLC lifted its stake in shares of Sight Sciences by 317.4% in the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after purchasing an additional 38,248 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the period. Finally, State Street Corp increased its position in shares of Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SGHT. UBS Group assumed coverage on shares of Sight Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $5.50 target price for the company. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Lake Street Capital cut shares of Sight Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $10.00 to $5.00 in a research note on Monday, November 4th. Citigroup decreased their price target on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.